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INCT de Sangue, Hematology Center, School of Medicine, University of Campinas — UNICAMP, Campinas, Sao Paulo, BrazilSickle cell disease (SCD) comprises a group of genetic disorders in before one year of age in SCA and the adhesion of reticulocytes to the
which the red blood cells (RBCs) produce abnormal sickle haemoglobin
(HbS) that can polymerise when oxygen concentrations are low. The
clinical manifestations of SCD are numerous, and vary from patient to
patient, but recurrent vaso-occlusive processes can cause significant
organ damage, resulting in increased morbidity and mortality in these
individuals (Kato et al., 2009). Polymerised HbS confers a characteristic
sickle shape to the RBC, in association with other cellular alterations;
furthermore, these RBCs are more likely to rupture, releasing damaging
cell-free haemoglobin (Hb) into the circulation (haemolysis), with
significant consequences that include vascular nitric oxide (NO) con-
sumption and oxidative stress (Kato et al., 2009). Newborn and very
young infants with sickle cell anaemia (SCA) still produce significant
amounts of foetal haemoglobin (HbF), the Hb that is made during intra-
uterine life, although this HbF production will begin to decline after the
first few months due to the Hb-switching process (Quinn, 2013). As
high concentrations of HbF inhibit the polymerisation of HbS, young
infants are asymptomatic and are generally thought to display little in
the way of pathophysiological alterations.
In the current issue of E-BioMedicine, Brousse et al. (in press) report
intriguing data to show that very young asymptomatic SCA infants,
whilst still producing very high total levels of HbF, demonstrate signifi-
cant alterations in reticulocyte membrane protein expression, in associ-
ation with reticulocytosis. The infants with SCA studied by Brousse and
colleagues were aged approximately 3–6 months and presented total
HbF levels of 41.2 (±11.2) %, a level much higher than that generally
sought during HbF-inducing hydroxycarbamide (hydroxyurea) therapy
in SCA adults (McGann and Ware, 2011). However, despite presenting
levels of total HbF thought to be protective in SCA, the adhesion mole-
cule expression profile on the reticulocytes of these children was
altered. Changes in adhesion molecule presentation on the erythroid
surface can confer alterations in cellular adhesion and augmented RBC
adhesive properties have been consistently observed in SCA, where
erythroid cell adhesive interactions are believed to contribute to the ini-
tiation and propagation of vaso-occlusive processes (Colin et al., 2014).
As such, the alterations observed in the expression profile of major ad-
hesion molecules on the reticulocyte surface of young infants could
have some important pathophysiological consequences; splenic vaso-
occlusion and the onset of hyposplenism, for example, usually occurDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.12.006.
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(Brousse et al., 2014, in press). Furthermore, although longitudinal data
are required for confirmation, the circulation of stress reticulocytes and
reduced Hb levels observed in these infants could be suggestive of
haemolytic anaemia. Given the known hazards of haemolysis (Kato
et al., 2009), it would seem of importance to characterise these events
further in young infants with a view to determining whether clinical
approaches to limit haemolysis should considered even before the
emergence of symptomology.
The distribution of HbF among HbF-containing red cells (F-cells)
varies between SCA individuals (Horiuchi et al., 1995), and this study
also highlights recent suggestions that the distribution of HbF among
red cells is more important than the total amount of HbF produced, in
terms of its protective effects (Steinberg et al., 2014), as the concentra-
tion of HbF in each F-cell must be sufficient to interfere in HbS polymer-
isation and therefore reduce the symptoms of SCA (Steinberg et al.,
2014). Co-inheritance of hereditary persistence of HbF (HPFH) together
with HbS, for example, typically induces levels of approximately 30 %
HbF in patients; this HbF, however, is usually distributed among all
the red cells and, consequently, these individuals are asymptomatic
(Steinberg et al., 2014; Ngo et al., 2012). In infants with SCA, the mean
HbF/F-cell content is known to drop drastically during the first year of
life, whilst the percentage of HbF cells remain high (Marcus and Ware,
1999), although the distribution of HbF concentrations in the F-cells is
not known. Thus, Brousse and colleagues' observation that very high
levels of global HbF did not completely protect young infants from red
cell alterations and reticulocytosis could indicate the occurrence of a
heterocellular distribution of HbF in these patients, whereby inhibition
of HbS polymerisation may not occur in a subpopulation of erythroid
cells. Whilst the success of hydroxycarbamide as a therapy for SCA is
undeniable, a growing body of evidence indicates that its extensive clin-
ical benefits may lie not only in its ability to elevate HbF, but may also
occur via HbF-independent mechanisms (McGann and Ware, 2011).
Researchers in the field continue to develop drugs and approaches
that focus on elevating HbF; while the importance of augmenting HbF
in SCA is irrefutable, care should be taken to ensure that HbF is elevated
in a pan-cellular manner and that combination drug approaches are
used to target other aspects of SCA pathophysiology.Conflicts of Interest
The author declares no conflicts of interest relevant to this
commentary.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
103N. Conran / EBioMedicine 2 (2015) 102–103Acknowledgements
The author would like to thank Prof. Fernando F. Costa for the
valuable discussion regarding the preparation of this commentary.
References
Brousse, V., Buffet, P., Rees, D., 2014. The spleen and sickle cell disease: the sick(led)
spleen. Br. J. Haematol. 166 (2), 165–176.
Brousse, V., Colin, Y., Pereira, C., et al., 2015. Erythroid adhesion molecules in sickle cell
anemia infants: insights into early pathophysiology. E-BioMedicine http://dx.doi.
org/10.1016/j.ebiom.2014.12.006 (in press).
Colin, Y., Le Van, Kim C., El Nemer, W., 2014. Red cell adhesion in human diseases. Curr.
Opin. Hematol. 21 (3), 186–192.
Horiuchi, K., Osterhout, M.L., Kamma, H., Bekoe, N.A., Hirokawa, K.J., 1995. Estimation of
fetal hemoglobin levels in individual red cells via fluorescence image cytometry.
Cytometry 20 (3), 261–267.Kato, G.J., Hebbel, R.P., Steinberg, M.H., Gladwin, M.T., 2009. Vasculopathy in sickle cell
disease: biology, pathophysiology, genetics, translational medicine, and new research
directions. Am. J. Hematol. 84 (9), 618–625.
Marcus, S.J., Ware, R.E., 1999. Physiologic decline in fetal hemoglobin parameters in
infants with sickle cell disease: implications for pharmacological intervention.
J. Pediatr. Hematol. Oncol. 21 (5), 407–411.
McGann, P.T., Ware, R.E., 2011. Hydroxyurea for sickle cell anemia: what have we learned
and what questions still remain? Curr. Opin. Hematol. 18 (3), 158–165.
Ngo, D.A., Aygun, B., Akinsheye, I., et al., 2012. Fetal haemoglobin levels and haematolog-
ical characteristics of compound heterozygotes for haemoglobin S and deletional
hereditary persistence of fetal haemoglobin. Br. J. Haematol. 156 (2), 259–264.
Quinn, C.T., 2013. Sickle cell disease in childhood: from newborn screening through transition
to adult medical care. Pediatr. Clin. N. Am. 60 (6), 1363–1381.
Steinberg, M.H., Chui, D.H., Dover, G.J., Sebastiani, P., Alsultan, A., 2014. Fetal hemoglobin
in sickle cell anemia: a glass half full? Blood 123 (4), 481–485.
